

5th July 2018

Resonance Health announces Alliance Partner Agreement with Blackford Analysis

Resonance Health Limited (ASX: RHT) ("Resonance Health") announced today that it has signed an Alliance Partner Agreement ("Agreement") with Blackford Analysis Limited ("Blackford").

Blackford provides a single platform that enables healthcare providers to quickly access and manage medical image analysis applications and AI algorithms that add clinical value. The platform allows healthcare providers to use imaging information efficiently and reduce the cost of care while improving diagnostic confidence and patient outcomes. The collaboration allows all of Blackford's current and future customers access to Resonance Health products.

The Blackford Platform integrates directly with PACs systems used by hospitals, including those provided by channel partners such as Intelrad and eRAD. The Resonance Health product FerriSmart® will now integrate seamlessly with the Blackford Platform, allowing for easy access from existing clinical workflows to improve diagnostic confidence, reduce the cost of care, and add clinical value.

This agreement gives Blackford the right to promote, market, sell, distribute, and license FerriSmart® directly and/or via resellers. FerriScan® and HepaFat-Scan® are also listed in the agreement and Resonance Health may subsequently authorise Blackford to integrate these with, or offer these in connection with, the Blackford platform. Work will now commence to integrate FerriSmart® with the Blackford platform. Blackford provides services in the United States, Canada, UK, Australia, and New Zealand.

Blackford CEO, Ben Panter said this of the alliance: "We look forward to working with Resonance Health to provide our customers and channel partners quick access to FerriSmart through our single platform, to help provide additional clinical value for patients."

Resonance Health's CEO, Alison Laws commented: "Integration into existing radiology workflows will mean seamless accessibility for our products across a new customer base, allowing us to provide future customers with the highest quality data for use in the clinical management of patients. We are very pleased to be working with Blackford to deliver our services as part of the Blackford platform".

Alison Laws

Chief Executive Officer

For further information please contact:

Chad Tondut
Communications Manager, Resonance Health
E: chadt@resonancehealth.com P: +61 (0)8 9286 5300

Blackford

Blackford provide a single platform to quickly access and manage regulatory approved medical image analysis applications and AI algorithms that add clinical value. Easily integrated into existing workflows, the platform provides actionable information that allows healthcare providers to use imaging information smartly and reduce the cost of care, while improving diagnostic confidence and patient outcomes. Founded in 2010, and with operations in the United Kingdom and the United States, Blackford Analysis is backed by TRI Cap, Old College Capital, and Archangel Investors, one of the UK's leading business angel syndicates. For more information, visit www.blackfordanalysis.com.

Blackford's role in the distribution

Blackford will promote, market, sell, license, sub-license and distribute Resonance Health products globally ("Territories"). All costs relating to the promotion, marketing, sale and distribution of licenses for the Products by Blackford will be borne by Blackford. Blackford will handle any and all contacts with end users to whom Blackford has entered into licenses for Resonance Health products. Blackford is responsible for providing first line support to end users.

Resonance Health's role in the distribution

Subject to the fulfilment by Blackford of its first line support obligations, Resonance Health will provide second line support to Blackford in connection with the Resonance Health products distributed by Blackford to end users, in accordance with the contract.

Contract details

The agreement grants Blackford a non-exclusive, non-transferable, sub-licensable, non-assignable right to integrate and combine Resonance Health products with, or sell and license Resonance Health products in connection with the host application as applicable; promote, market, sell, and distribute licenses for Resonance Health products to end users including the right to offer Resonance Health products on a software-as-a-service basis in the Territories, directly or through resellers; sell or provide consulting services for the products distributed by Blackford to the end users in the Territories; and sell and provide first line support services to the Resonance Health products distributed by Blackford to end users in the Territories, in accordance with and subject to the terms of the agreement. All costs relating to the promotion, marketing, sale, and distribution of licenses for the Resonance Health products by Blackford will be borne by Blackford. The initial term of the Agreement is one year and following the initial term the Agreement will be automatically renewed for consecutive one-year periods, unless either Party advises the other Party in writing at least 30 days prior to the initial term or any subsequent term of its intent not to renew the Agreement, in which case the Agreement will terminate at the end of the initial term or subsequent term as the case may be. Notwithstanding any provisions to the contrary in the Agreement, either Party may terminate the Agreement in the case of a material breach by the other Party of its obligations under the Agreement.